Skip to main content

Table 3 Endoscopic findings and comparison between rebleeding and no-rebleeding group

From: Development and validation of a model to predict rebleeding within three days after endoscopic hemostasis for high-risk peptic ulcer bleeding

Characteristic

Total

Rebleeding

Non-rebleeding

P

N = 386

N = 48

N = 338

Ulcer location [No. (%)]

   

0.282

 Fundus

18 (4.7)

1 (2.1)

17 (5)

 

 Body

63 (16.3)

7 (14.6)

56 (16.6)

 

 Angulus

18 (4.7)

1 (2.1)

17 (5)

 

 Antrum

41 (10.6)

4 (8.3)

37 (10.9)

 

 Duodenum

193 (50)

32 (66.7)

161 (47.6)

 

 Anastomotic site

53 (13.7)

3 (6.3)

50 (14.8)

 

Ulcer size ≥ 2 cm [No. (%)]

35 (9.1)

7 (14.6)

28 (8.3)

0.249

Stigmata of hemorrhage [No. (%)]

   

0.001

 Forrest Ia

22 (5.7)

7 (14.6)

15 (4.4)

 

 Forrest Ib

144 (37.3)

26 (54.2)

118 (34.9)

 

 Forrest IIa

121 (31.1)

7 (14.6)

114 (33.7)

 

 Forrest IIb

99 (25.6)

8 (16.7)

91 (29.6)

 

Methods of endoscopic hemostasis [No. (%)]

   

0.453

 Injection therapy

224 (58)

30 (62.5)

194 (57.4)

 

 Thermal coagulation

18 (4.7)

2 (4.2)

16 (4.7)

 

 Mechanical therapy

60 (15.5)

4 (8.3)

56 (16.6)

 

 Combination therapy

84 (21.8)

12 (25)

72 (21.3)

Â